EXPERIMENTAL DRUG DEVELOPMENT CENTR AGENCY FOR SCIENCE 10 BIOPOLIS ROA TECHN AND RESEARCH 05 01CHROM

Parent Organization: Agency for Science, Technology and Research (A*STAR)

Address: 10 Biopolis Road, TECHNOS, 05-01CHROM, Singapore

Type of Business: Research and Development Institution

Company Introduction:

The Experimental Drug Development Centre (EDDC) is Singapore's national platform for drug discovery and development. It operates under the umbrella of the Agency for Science, Technology and Research (A*STAR), a leading government agency dedicated to fostering scientific research and innovation.

EDDC is not a factory (manufacturing facility) nor is it a trading company. Instead, its primary function is to bridge the gap between scientific breakthroughs and clinical applications. The centre focuses on translating cutting-edge research into novel drug candidates, driving preclinical and early clinical development of therapeutics.

Its core mission involves identifying and validating drug targets, optimizing lead compounds, conducting preclinical pharmacology and toxicology studies, and facilitating early-phase clinical trials. EDDC collaborates extensively with academic institutions, biotechnology firms, and pharmaceutical partners globally to accelerate the development of new medicines, particularly in areas of significant unmet medical need. Its work is crucial for advancing biomedical science and improving public health.

Based on the information provided, the Experimental Drug Development Centre (EDDC) of the Agency for Science, Technology and Research (A*STAR) in Singapore, located at 10 Biopolis Road, is primarily a research and development organization.

There is no readily identifiable commercial entity named "CHROM Company" that directly produces or sells commercial products as part of or under the EDDC or A*STAR.

EDDC's core activities involve:

* Developing novel drug candidates and therapeutic modalities.

* Creating innovative drug discovery and development platforms.

* Generating intellectual property in the pharmaceutical and biotech sectors.

These outputs are typically advanced through collaborative partnerships, licensing agreements with pharmaceutical companies, or further clinical development, rather than being directly sold as commercial products by EDDC itself.